Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

Efficacy and Safety of Intravenous Infusion of SHR-1906 in Patients With Idiopathic Pulmonary Fibrosis: a Multicenter, Randomized, Double-blind, Parallel Placebo-controlled Phase II Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05722964
• Other study ID #: SHR-1906-201
• Status: Recruiting
• Phase: Phase 2
• Start date: March 29, 2023
• Est. completion date: May 31, 2024

Study information

• Verified date: January 2023
• Source: Guangdong Hengrui Pharmaceutical Co., Ltd
• Contact: Luyao Dong
• Phone: 18205132527
• Email: luyao.dong[@]hengrui.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of intravenous SHR-1906 in the treatment of idiopathic pulmonary fibrosis. The study is divided into four stages: screening period, baseline period, treatment period and safe follow-up period. It is planned that 108 patients will be randomly assigned to the following three treatment groups for treatment

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: May 31, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age 40 to 80, inclusive, at the time of screening;

2. IPF diagnosed according to ATS/ERS/JRS/ALAT guidelines (2022) (HRCT diagnosis UIP type/possible UIP type (standard HRCT confirmed by central review in recent 3 months) with or without pathological UIP type/possible UIP type (pathology refers to frozen lung biopsy or surgical/thoracoscopic lung biopsy);

3. 90% = FVCpp = 45% during screening period and the first day;

4. The percent of predicted DLCO value (corrected by Hb value) at screening is = 30% and = 90%;

5. Before the screening period, pirfenidone or nidanib with stable dose = 8 weeks (pirfenidone = 1200 mg/denidanib = 200 mg/d) can continue to maintain treatment with stable dose during the study period; Or at least 4 weeks before the screening period, pirfenidone or nidanib was not used (pirfenidone or nidanib was refused due to intolerance or various factors) ;

Exclusion Criteria:

1. Evidence of any of the following significant obstructive pulmonary disease: (1) The ratio of forced expiratory volume/forced vital capacity (FEV1/FVC) at the first second is < 0.70 (after using bronchodilator) or (2) HRCT shows that emphysema is greater than fibrosis;

2. Interstitial lung diseases (ILD) other than IPF include but are not limited to: any other type of idiopathic interstitial pneumonia; Lung diseases related to contact with fibroblasts or other environmental toxins or drugs; Other types of occupational lung diseases; Granulomatous lung disease; Pulmonary vascular disease; Systemic diseases include vasculitis infectious diseases (i.e. Tuberculosis) and connective tissue diseases If the diagnosis is unclear, serological examination and/or multidisciplinary expert group review should be conducted to confirm IPF or other types of ILD diagnosis;

3. A history of other types of respiratory diseases, including respiratory tract, lung parenchyma, pleural cavity, mediastinum, diaphragm or chest wall diseases or disorders, such as acute respiratory infection, active tuberculosis, etc., which researchers believe will affect the primary endpoint of the study or otherwise affect the participation of subjects in the study;

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• SHR-1906
Intravenous injection
• SHR-1906
Intravenous injection
• Placebo
Placebo,Intravenous injection

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Guangdong Hengrui Pharmaceutical Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in FVC% (Percent of Predicted FVC value) to week 24		Baseline, Week 24
Secondary	Change from Baseline in FVC (L) to Week 4, 8, 12, 16, 20, 24		Baseline, Week 4, 8, 12, 16, 20, 24
Secondary	Change from Baseline in FVC% (Percent of Predicted FVC value) to Week 4, 8, 12, 16, 20		Baseline, Week 4, 8, 12, 16, 20
Secondary	Change from Baseline in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) to Week 12 and Week 24		Baseline, Week 12 and Week 24
Secondary	Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Scores to Week 12 and Week 24		Baseline, Week 12 and Week 24]
Secondary	Number of Praticipants with an Acute Exacerbation of IPF		Start of Treatment to end of study (approximately 28 weeks)
Secondary	All-cause mortality		Start of Treatment to end of study (approximately 28 weeks)
Secondary	Adverse events		Start of Treatment to end of study (approximately 28 weeks)
Secondary	Serum concentration of SHR-1906		Start of Treatment to end of study (approximately 28 weeks)
Secondary	Proportion of anti-SHR-1906 antibody (ADA) formed during the study from baseline		Start of Treatment to end of study (approximately 28 weeks)